Clinical Neuropharmacology · 2005 · 30 citations · 27 references
MedicinePharmacologyPharmacotherapyMovement DisordersNeuropharmacologyPsychopharmacologyAntipsychotic PharmacologyDrug-induced Movement DisordersMovement Disorder PharmacotherapyPediatric Movement DisordersAdverse Neuropsychiatric EffectsAntipsychotic-induced Movement DisordersDopamine-related Movement DisordersMedical Records ReviewMedication-induced Neuropsychiatric EffectsNeuropsychiatric Adverse EffectsNeuropsychiatric EffectsPediatric Drug-induced Movement Disorders
OBJECTIVE: Two cases are described of dystonic rabbit syndrome induced by citalopram. This syndrome is a movement disorder with a 5-Hz rhythmic vertical motion of the mouth and lips without involvement of the tongue. METHOD: The patients were interviewed and examined, and additional history was taken from the medical records. The Naranjo adverse drug reaction rating scale was applied. Relevant literature was reviewed. RESULTS: Two patients developed dystonic rabbit syndrome soon after starting escitalopram 10 mg/day or citalopram 5 mg/day. Neither patient had any past or current exposure to a dopamine-blocking drug or any history of movement disorder. [Es]citalopram discontinuation led to disappearance of the movement disorder. The Naranjo scale indicates high probability of dystonic rabbit syndrome from citalopram. CONCLUSION: Citalopram can rapidly induce dystonic rabbit syndrome. This effect suggests that for some patients citalopram has neuropsychiatric effects similar to those of a dopamine-blocking antipsychotic drug. This might be of concern with patients who cannot communicate well (eg, young children; patients with dementia, developmental disabilities, or aphasia).
27
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations
Discontinuation of Use and Switching of Antidepressants
Scott Bull, Xue‐Jin Hu, Enid M. Hunkeler et al. · JAMA · 2002 · 358 citations
Discontinuing or Switching Selective Serotonin-Reuptake Inhibitors
Scott Bull, Enid M. Hunkeler, Janelle Y Lee et al. · Annals of Pharmacotherapy · 2002 · 187 citations
Fluoxetine and extrapyramidal side effects
David M Coulter, Peter I. Pillans · American Journal of Psychiatry · 1995 · 159 citations